3D model application in preclinical studies is no longer a dream – it’s happening, and happening fast to support the rise of precision medicine. At the 5th PREDiCT: 3D Oncology & Tissue Models Summit, we shared fresh case studies and data presented by drug developers and expert partners on their journeys, including new model validation, selection strategy, reproducibility techniques.
This is the only industry-led summit focusing on real world application of 3D models in drug discovery and development. The 2020 agenda delved further into advanced organoids, organ-on-chips and other emerging 3D platforms in oncology, as well as other therapeutic areas. It’s our mission to help you expedite your pipeline into clinic with confidence in safety and efficacy – which will ultimate benefit patients worldwide.
Over 120+ senior leaders joined from the likes of Pfizer, Takeda, AstraZeneca, NIH and award-winning academic institutions. The 2-tracked program boasted:
- 30+ latest case studies of 3D models applications in drug discovery and development – lessons learned and opportunities
- Regulatory agencies’ expectations and what data is accepted for a smooth filing
- How to overcome translational, screening, reproducibility and validation challenges to boost confidence in your 3D selection
- Form partnerships and alliance with industry KOLs – be inspired and start making a change in your drug discovery and preclinical development program